Barbara Jauregui

Barbara Jauregui
George Washington University | GW

MD MSc
Global health advisor - Ed innovation fanatic

About

33
Publications
9,140
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
721
Citations
Introduction
I’m a highly motivated Argentine-American physician with postgraduate studies in Clinical Effectiveness and Healthcare Quality Improvement. I have twenty years of international experience in public health in both government and non-profit organizations, public health program development and implementation, clinical and operational research, and capacity building.
Additional affiliations
April 2010 - present
George Washington University
Position
  • Adjunct Professorial Lecturer
December 2007 - August 2014
Pan American Health Organization (PAHO)
Position
  • Specialist on evidence-based policy
January 2005 - December 2006
Institute for Clinical Effectiveness and Health Policy
Position
  • Researcher

Publications

Publications (33)
Article
Full-text available
Author summary The use of biomarkers to measure immune responses in serum is crucial for understanding population-level exposure and susceptibility to human pathogens. Advances in sample collection, multiplex testing, and computational modeling are transforming serosurveillance into a powerful tool for public health program design and response to i...
Preprint
Full-text available
The use of biomarkers to measure immune responses in serum is crucial for understanding population-level exposure and susceptibility to human pathogens. Advances in sample collection, multiplex testing, and computational modeling are transforming serosurveillance into a powerful tool for public health program design and response to infectious threa...
Preprint
Full-text available
BACKGROUND Real World Data (RWD) and Real World Evidence (RWE) have an increasingly important role in clinical research and health care decision making in many countries. In order to leverage RWD and generate reliable RWE, a framework must be in place to ensure that the data is well-defined and structured in a way that is semantically interoperable...
Article
Full-text available
Background: Real-world data (RWD) and real-world evidence (RWE) are playing increasingly important roles in clinical research and health care decision-making. To leverage RWD and generate reliable RWE, data should be well defined and structured in a way that is semantically interoperable and consistent across stakeholders. The adoption of data sta...
Article
Full-text available
Background: The Region of the Americas has a long history of implementing maternal and neonatal immunization (MNI) programs. Our study aimed to understand the state of MNI policies, strategies and implementation practices in Latin America (LA). Methods: Study conducted in 5 middle-income countries: Argentina, Brazil, Honduras, Mexico and Peru. T...
Article
The value of robust and responsible data sharing in clinical research and healthcare is recognized by patients, patient advocacy groups, researchers, journal editors, and the healthcare industry globally. Privacy and security concerns acknowledged, the act of exchanging data (interoperability) along with its meaning (semantic interoperability) acro...
Article
Full-text available
A National Immunization Technical Advisory Group (NITAG) is an expert advisory committee that provides evidence-based recommendations to the Ministry of Health (MoH) to guide immunization programs and policies. The World Health Organization (WHO), the Initiative for Supporting National Independent Immunization and Vaccine Advisory Committees (SIVAC...
Article
Full-text available
The increasing geographical spread and disease incidence of arboviral infections are among the greatest public health concerns in the Americas. The region has observed an increasing trend in dengue incidence in the last decades, evolving from low to hyperendemicity. Yellow fever incidence has also intensified in this period, expanding from sylvatic...
Article
Full-text available
http://www.appliedclinicaltrialsonline.com/turning-point-clinical-research-global-data-standardization?topic=230&CID=actdirect.2355405.APCT%2A%2520Applied%2520Clinical%2520Trials%2520Direct%2520%7C%2520Bi-monthly&eid=191421684&bid=2355405
Data
Table S1. The Suite of Standards for Defining, Collecting, Analyzing, and Exchanging Data for Medical Research.
Article
Full-text available
Maternal and neonatal immunization (MNI) is a core component of the new immunization model in the Americas, which transitioned from immunization of children to that of the entire family. Immunization during pregnancy protects the mother and the fetus by providing the neonate with maternal antibodies against disease. It has the potential to impact e...
Article
Full-text available
This article synthesizes the important lessons learned from polio eradication in the Region of the Americas, including initial and more recent challenges and best practices, as well as particular factors surrounding attainment of this ambitious goal. Using documents, interviews, and country surveys, the authors describe and analyze the strategies a...
Article
Full-text available
Objectives: To summarize and critically evaluate the evidence on the impact and effectiveness of meningococcal vaccination programs around the world in order to inform decisionmaking in Latin America and the Caribbean. Methods: A review of the literature was conducted following several components of the Preferred Reporting Items for Systematic R...
Article
Full-text available
The synchronized introduction of the inactivated polio vaccine (IPV) and the switch from trivalent oral polio vaccine (tOPV) to bivalent oral polio vaccine (bOPV) has constituted an effort without precedents, and with astonishing results. Within the established time frame, all countries in our region managed to carry out the decision, planning, and...
Article
Pan American Health Organization's (PAHO) ProVac Initiative aims to strengthen countries' technical capacity to make evidence-based immunization policy. With financial support from the Bill and Melinda Gates Foundation, PAHO established the ProVac International Working Group (IWG), a platform created for two years to transfer the ProVac Initiative'...
Article
To describe a cost-effectiveness analysis of 10- or 13-valent pneumococcal conjugate vaccine (PCV10 or 13) introduction in Paraguay compared to no vaccination. The integrated TRIVAC vaccine cost-effectiveness model (version 2.0) jointly developed by the Pan American Health Organization's ProVac Initiative and the London School of Hygiene & Tropical...
Article
The Pan American Health Organization (PAHO) created the ProVac Initiative in 2004 with the goal of strengthening national technical capacity to make evidence-based decisions on new vaccine introduction, focusing on economic evaluations. In view of the 10th anniversary of the ProVac Initiative, this article describes its progress and reflects on les...
Article
Full-text available
Governments have the authority and responsibility to ensure vaccination for all citizens. The development of vaccination legislation in Latin America and the Caribbean (LAC) parallels the emergence of sustainable, relatively autonomous, and effective national immunization programs. We reviewed vaccination legislation and related legal documents fro...
Article
New vaccines have been demonstrated to be effective in reducing morbidity and mortality, particularly in children, but come at increased costs to societies, governments, and their national immunization programs compared with other traditional childhood vaccines. Rational allocation of available resources requires systematic collection of the eviden...
Conference Paper
Purpose: When choosing between models to inform resource allocation decisions, policymakers are often forced to trade complexity, accuracy, and flexibility for ease of use, computational speed, and transparency of model logic. The ProVac Initiative develops model-based tools and provides technical assistance to Latin American countries to build loc...
Article
The majority of industrialized and some developing countries have established technical advisory bodies to guide and formulate national immunization policies and strategies. These are referred to as National Immunization Technical Advisory Groups (NITAGs), WHO and its partners have placed a high priority on assisting in the establishment or strengt...
Article
Full-text available
There are many challenges to ensuring that people in developing countries have equitable access to new vaccines. Two of the most important are having the capacity to make evidence-based new vaccine policy decisions in developing countries, and then when appropriate actually distributing those new vaccines to those who will most benefit from them. B...
Article
Since the 10-valent pneumococcal conjugate vaccine (PCV-10) and 13-valent pneumococcal conjugate vaccine (PCV-13) were recently licensed for use in Argentina, both vaccines were evaluated to estimate the costs, health benefits and cost-effectiveness of adding a PCV to the routine child immunization schedule. The integrated TRIVAC vaccine cost-effec...
Article
Rotavirus, pneumococcal conjugate and HPV vaccines have the potential to make substantial gains in health, specifically in reducing child mortality and improving women's health. Decisions regarding new vaccine introduction should be grounded in a broad evidence base that reflects national conditions. In this paper, we describe the Pan American Heal...
Article
Full-text available
Reducing and eliminating vaccine-preventable diseases requires evidence-based and informed policy decision making. Critical to determining the functionality of the decision-making process for introduction of a new vaccine is understanding the role of the national immunization technical advisory group (ITAG) in each country. The aim of this study is...
Article
Despite the available knowledge and tools to prevent cervical cancer, it remains the second most common cancer in women, with four-fifths of the cases occurring in developing countries. Projections are for a 90% increase in global cervical cancer cases by 2020 if no additional public-health interventions are implemented. Prophylactic human papillom...

Network

Cited By